-
Basel, March 31, 2022 — Novartis today announced that the European Commission (EC) has approved Beovu® (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Today’s approval in DME represents the second indication for Beovu granted by the EC, which was first approved for the treatment of wet age-related…OphthalmologyEye DisordersEye CareDiabetes
-
Basel, December 22, 2021 — Novartis announced today that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics.OphthalmologyFuture of HealthcareEye CareCell and Gene Therapy
-
Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edemaBasel, October 13, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and that the European Medicines Agency (EMA) has validated the type-II variation application for Beovu® (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME…OphthalmologyEye Care
-
Novartis is working with partners around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care.Access to HealthcareEye CareEye DisordersOphthalmology -
Eyesight initiatives are restoring vision – and hope – to thousands of people in Southeast Asia by expanding equitable access to eye care.
Access to HealthcareEye CareEye DisordersOphthalmologyPatient Voices -
Basel, August 17, 2021 — Novartis today announced positive results from two Phase III clinical trials assessing Beovu® (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year two of the pivotal KITE* trial evaluated Beovu on up to 16-week dosing intervals, and the one-year KINGFISHER study evaluated Beovu…OphthalmologyEye Care
-
Basel, 21. September 2021 — Novartis hat heute die Übernahme von Arctos Medical bekanntgegeben. Das Unternehmen erweitert dadurch sein Portfolio in der Augenheilkunde um das präklinische AAV*-Gentherapieprogramm sowie die entsprechende Technologie von Arctos. Die Übernahme unterstreicht das Engagement von Novartis, Behandlungsmöglichkeiten für…OphthalmologyEye CareCell and Gene Therapy
-
Bâle, le 21 septembre, 2021 — Novartis a annoncé aujourd’hui avoir acquis Arctos Medical, ajoutant à son portefeuille d’ophtalmologie un programme préclinique de thérapie génique AAV basé sur l’optogénétique et la technologie exclusive d’Arctos. Cette acquisition souligne l’engagement de Novartis dans la recherche de traitements pour les patients…OphthalmologyEye CareCell and Gene Therapy
-
Basel, September 21, 2021 — Novartis today announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition underscores the Novartis commitment to finding treatments for patients with vision loss and the potential of…OphthalmologyEye CareCell and Gene Therapy
-
Basel, September 14, 2020 — Novartis today reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME). The trial met its primary and key secondary endpoints, demonstrating non-inferiority for Beovu versus aflibercept 2 mg in mean change in…Reimagine MedicineOphthalmologyInnovation
-
Basel, September 14, 2020 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP), has approved an update to the Beovu® (brolucizumab) Summary of Product Characteristics (SmPC) to include additional information regarding retinal vasculitis and retinal vascular occlusion1. Typically, these events occurred in the…OphthalmologyInnovation
-
Basel, October 5, 2020 — Novartis today announced that results of two new post-hoc analyses of the Phase III HAWK and HARRIER clinical trials in wet age-related macular degeneration (AMD) were presented at the EURETINA 2020 virtual congress. The first analysis demonstrated fewer Beovu® (brolucizumab) patients had early persistent fluid, defined as…Reimagine MedicineOphthalmologyEye Care
-
Novartis is working with partners around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care.
-
Eyesight initiatives are restoring vision – and hope – to thousands of people in Southeast Asia by expanding equitable access to eye care.